Adrian Adams tapped to run Auxilium, Anido out; Franco retires from the helm at Dara;

@FierceBiotech: 5 Innovative Michigan device/diagnostic companies. Fascinating tech profiled here by @FierceMedDev. Report | Follow @FierceBiotech

@JohnCFierce: Auxilium (Xiaflex) gets a sales guy to run the company. Punch up sales, work a deal? Maybe. But what biotech isn't in play these days? | Follow @JohnCFierce

@MaureenFierce: Report: Cancer vaccines, flu vaccines, and pneumococcal vaccines will experience the most growth in coming years. | Follow @MaureenFierce

@FierceMedDev: Abbott starts trial to evaluate the Absorb bioresorbable vascular scaffold versus metallic DES. Release | Follow @FierceMedDev

> Adrian Adams (photo), a well-known biotech exec who helmed Neurologix and Inspire Pharmaceuticals, has been brought in as the new CEO of Malvern, PA-based Auxilium Pharmaceuticals ($AUXL). He's replacing Armando Anido, who stepped down after "discussions with the company's board." Auxilium release

> Richard Franco, 70, has announced plans to retire from his position as CEO of Dara BioSciences. News

> The FDA has approved an 84-mg dose of Antares' oxybutynin gel for overactive bladder. Item

> Cubist has extended its offer to buy shares in Adolor. Report

> The FDA plans to host a public meeting Dec. 16 to review its user fee program for biosimilars. Story

Pharma News

FiercePharma: AstraZeneca's cutting 1,150 sales jobs, about 24% of U.S. organization. Release | Follow @FiercePharma

> AstraZeneca cuts 1,150 U.S. jobs, adds on in China. Item

> HHS chief smacks down FDA's Plan B decision. Report

Vaccines News

> Study: Afternoon vaccines may be better for babies. Report

> EU wants power to negotiate flu vaccine prices. Story

> Takeda unveils new vaccine business headed by Gates Foundation exec. News

> LigoCyte posts positive results from norovirus vaccine trial. Item

Manufacturing News

> Catalent to go disposable in new plant. News

> Analysts ponder takeover of ailing Hospira. Article

> CMO capacity expansions mirror market. Report

> FDA notes lack of Novartis exec response in 3-site warning. News

> Samsung, Biogen Idec team on biosimilars. Story

> Pfizer briefs NJ public on Superfund site cleanup. Item

And Finally... Researchers at the Mayo Clinic in Florida say two drugs--ixabepilone and sunitinib--never used in combination before in ovarian cancer triggered the destruction of 70% of the cancer cells resistant to commonly used chemotherapy agents. Report